Full history for every metric is available with a Kvantra account
Small Pharma Inc. (DMTTF)
Key financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | - | - | - | 0 | 0 | 0 | 0 |
| Operating profit | CAD m | -25 | -24 | |||||
| Net profit | CAD m | - | - | - | -7 | -22 | -23 | -23 |
| EPS reported | CAD | -0.07 | -0.07 | |||||
| Operating cashflow per share | CAD | -0.07 | -0.07 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.07 | -0.07 | |||||
| Free cash flow | CAD m | -22 | -22 | |||||
| Net debt | CAD m | -18 | -13 | |||||
| Book value equity | CAD m | 17 | 12 | |||||
| Book value per share | CAD | 0.05 | 0.04 | |||||
| Number of shares | m | 321.47 | 321.56 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.73 | 4.45 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -1.33 | -2.46 | |||||
| EV/EBITDA LTM | x | -0.48 | -1.66 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -77.00% | -44.67% | |||||
| FCF Yield | % | -74.99% | -40.58% | |||||
| Quality | ||||||||
| ROE | % | -133.11% | -78.43% | |||||
| ROIC | % | -128.32% | -128.32% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -36.49 | -39.55 | |||||
| Net Debt/EBITDA | x | 0.73 | 0.73 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -60.45% | -24.62% | |||||
| Net debt/Equity | x | -1.04 | -1.10 | |||||
| Gross debt/equity | x | 0.04 | 0.05 | |||||
Company overview
Small Pharma Inc. is a biotechnology firm focused on developing fast-acting psychedelic therapies, coupled with supportive psychological care, to address mental health conditions. Its flagship clinical initiative centers on N,N-dimethyltryptamine (DMT) assisted therapy designed to combat major depressive disorder. Specifically, its compound SPL026 is currently in Phase IIA clinical trials for MDD treatment. The company's preclinical pipeline also includes SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801, an oral formulation of 6-hydroxynorketamine. Founded in 2015, Small Pharma Inc. is headquartered in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Small Pharma Inc. (DMTTF)
Small Pharma Inc. is a biotechnology firm focused on developing fast-acting psychedelic therapies, coupled with supportive psychological care, to address mental health conditions. Its flagship clinical initiative centers on N,N-dimethyltryptamine (DMT) assisted therapy designed to combat major depressive disorder. Specifically, its compound SPL026 is currently in Phase IIA clinical trials for MDD treatment. The company's preclinical pipeline also includes SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801, an oral formulation of 6-hydroxynorketamine. Founded in 2015, Small Pharma Inc. is headquartered in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free